Analyse the risk factors for producing anti-HLA antibodies in patients with hematological diseases
Journal Title: Chinese Journal of Blood Transfusion - Year 2024, Vol 37, Issue 2
Abstract
Objective To explore the risk factors for the production of anti-HLA antibodies in patients with hematological diseases before hematopoietic stemcell transplantation. Methods The results and clinical data of 1 008 patients with hematological diseases in our hospital who underwent anti-HLA antibody testing were collected by using Luminex technology platform before transplantation from 2016 to 2018 for statistical analysis. Results The total positive rate of anti-HLA antibodies in 1 008 patients was 24.08%. Multivariate analysis showed that independent risk factors associated with the production of anti-HLA antibodies included age≥30 years old(P=0.046, OR1.467, 95%CI1.007-2.136), time from disease diagnosis to antibody testing≥41 days(P=0.000, OR1.830, 95%CI1.306-2.565), initial platelet count<20×109/L(P=0.020, OR1.543, 95%CI1.072-2.220), prior pregnancy(P=0.000, OR5.187, 95%CI3.689-7.293), transfusions before admission(P=0.001, OR1.762, 95%CI1.257-2.470)and total platelet transfusion volumes after admission≥30 U(P=0.000, OR2.352, 95%CI1.638-3.376). Age ≥30 years old(P=0.023, OR=1.839, 95%CI1.088-3.108)and prior pregnancy(P=0.042, OR=5.258, 95%CI1.062-26.038)are associated with the production of anti-HLA class Ⅰ and class Ⅱ antibodies, respectively. The time from disease diagnosis to antibody testing≥41 days(P=0.000, OR=2.873, 95%CI1.612-5.119), initial platelet count<20×109/L(P=0.008, OR=2.164, 95%CI1.225-3.822), prior pregnancy(P=0.002, OR=6.734, 95%CI1.993-22.751), transfusions before admission(P=0.001, OR=2.746, 95%CI1.531-4.925)and total platelet transfusion volumes after admission>30 U(P=0.006, OR=3.459, 95%CI1.416-8.451)are associated with the production of anti-HLA class Ⅰ and Ⅱ antibodies. Conclusion Older age, longer course of disease, lower PLT count, history of pregnancy and blood transfusion, and higher total amount of PLT transfusion are risk factors which affect the production of anti-HLA antibodies.Therefore, it is advisable to test for anti-HLA antibodies according to the situation before transplantation, which is of great value in guiding donor selection, monitoring antibody changes and improving transplant prognosis.
Authors and Affiliations
Kai JI, Lan WANG, Luyao CHEN, Xiaojing BAO, Xiaoni YUAN, Xiaojin WU, Jun HE
Keywords
Related Articles
- EP ID EP738761
- DOI 10.13303/j.cjbt.issn.1004549x.2024.02.007
- Views 7
- Downloads 0
Serological and molecular biological analysis of Aw43 subtype: report of two cases
Objective To conduct serological identification and molecular study of two patients with ABO ambiguous blood group. Methods The serological tests were conducted by the tube method. DNA direct sequencing was performed to...
Identification of a rare Ael subtype
Objective To identify and analyze a case of ABO discrepancy between forward and reverse blood grouping, and to provide reference for the identification of ambiguous blood group in clinical. Methods ABO and Rh blood group...
Blood consumption and clinical prognosis in patients with massive blood transfusion: a retrospective analysis
Objective To investigate the incidence of clinical massive blood transfusion in hospitals, the proportion of departments conducted massive blood transfusion and the current situation of component transfusion, so as to pr...
Influence of preoperative optimization of Hb level on perioperative blood transfusion and postoperative outcome in patients with preoperative anemia
Objective To investigate the effect of optimized preoperative hemoglobin (Hb) level on clinical outcome in patients undergoing coronary artery bypass grafting (CABG). Methods Retrospective analysis was performed on patie...
Influencing factors of the repeat reactive (RR) rates of minipools implicated in minipool(MP) nucleic acid testing(NAT) in Xiamen
Objective To analyze the influencing factors of the repeat reactive (RR) rates of minipools implicated in minipool (MP) nucleic acid testing(NAT) in Xiamen Blood Center, in order to provide reference for NAT. Methods Sam...